Page 6 - Kernel Flow News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cybin Announces Closing of Upsized Bought Deal Offering Company Has Raised Nearly CDN$90 Million to Date NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Cybin Inc. a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering including the exercise of the over-allotment option granted to the … Company Has Raised Nearly CDN$90 Million to Date NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN...

Mental Health Demand For Development Of Psychedelic Drug Therapies Is Increasing PALM BEACH, Fla., Jan. 12, 2021 /PRNewswire/ -- After being relegated to the margins of sincere scientific examination for about five decades, growing researchers and scientists are exploring the therapeutic value of psychedelic drugs and compounds that could be a new treatment option for people with depression. According to Data Bridge Market Research North America psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the mar...

HIGHLIGHTS Using Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules targeting neurological disorders. Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal brain activity before, during and after a psychedelic experience, enabling ...